0836 GMT - U.K. pharma could have some share-price volatility but the long-term outlook shouldn't be affected by U.S. President Trump's imposed tariffs on global imports that currently exempt drugs and vaccines, Shore Capital analyst Sean Conroy says in a note. The longer-term revenue targets for British pharma companies GSK and AstraZeneca extend beyond the remaining term of Trump and their fundamentals remain robust as populations are getting older and sicker, the analyst says. "Pharma often finds itself in the firing line when it comes to U.S. politics--given the prominence of drug prices on the U.S. political agenda and news cycle--however, more often than not there is a material difference between traveling and arriving, with the impact realized often far less draconian than initially feared," he says. GSK and AstraZeneca are both up 1.5% and 1.6%, respectively. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 04:36 ET (08:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。